Alireza Ebrahimi

Alireza Ebrahimi

Auto-generated profile, based on publicly available information

Alireza Ebrahimi

Department of Orthopaedic Surgery, Foot & Ankle Research and Innovation Laboratory (FARIL) Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Biochemistry Research International
Verified
Journal Article
Open access
PDF file
AEAlireza Ebrahimi
Alireza Ebrahimi
AKAmirhossein Kamyab
Amirhossein Kamyab
SHSahar Hosseini
Sahar Hosseini
SESedigheh Ebrahimi
Sedigheh Ebrahimi
SESoheil Ashkani Esfahani
Soheil Ashkani Esfahani
Coenzyme Q10 (CoQ10), commonly known as ubiquinone, is a vitamin-like component generated in mitochondrial inner membranes. This molecule is detected broadly in different parts of the human body in various quantities. This molecule can be absorbed by the digestive system from various nutritional sources as supplements. CoQ10 exists in three states: in a of reduced form (ubiquinol), in a semiquinone radical form, and in oxidized ubiquinone form in different organs of the body, playing a crucial role in electron transportation and contributing to energy metabolism and oxygen utilization, especially in the musculoskeletal and nervous systems. Since the early 1980s, research about CoQ10 has become the interest for two reasons. First, CoQ10 deficiency has been found to have a link with cardiovascular, neurologic, and cancer disorders. Second, this molecule has an antioxidant and free-radical scavenger nature. Since then, several investigations have indicated that the drug may benefit patients with cardiovascular, neuromuscular, and neurodegenerative illnesses. CoQ10 may protect the neurological system from degeneration and degradation due to its antioxidant and energy-regulating activity in mitochondria. This agent has shown its efficacy in preventing and treating neurological diseases such as migraine, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and Friedreich’s ataxia. This study reviews the literature to highlight this agent’s potential therapeutic effects in the mentioned neurological disorders.


23 September 2024 in Journal of Bone Oncology
Verified
Journal Article
Open access
ABAtefe Barzegari
Atefe Barzegari
FSFateme Salemi
Fateme Salemi
AKAmirhossein Kamyab
Amirhossein Kamyab
AAAdarsh Aratikatla
Adarsh Aratikatla
NNNegar Nejati
Negar Nejati
AEAlireza Ebrahimi
Alireza Ebrahimi
• Primary bone tumors (PBTs) have a low incidence, but cause significant patient burden. • CAR T-cell therapy has been used in treating hematological malignancies. • CAR T-cells may be used in solid tumors to improve survival in patients with PBTs. • This review summarizes findings on CAR T-cell therapy for PBTs.

12 November 2021 in International Journal of Dentistry
Verified
Journal Article
Open access
PDF file
HAHanie Ahmadi
Hanie Ahmadi
AEAlireza Ebrahimi
Alireza Ebrahimi
FGFarhad Ghorbani
Farhad Ghorbani
Background. Blood type is among the most important genetical characteristics of any individual and is shown to be correlated with the development of a variety of illnesses including dental diseases. Finding the association of ABO and Rh blood groups and impacted tooth is important in order to predict which population is more vulnerable to grow impacted third molars that could lead to making better intervention. The present investigation tried to take a small step in that regard, by evaluating the correlation between ABO and Rh blood groups and the most commonly impacted tooth, bony impacted third molars among Iranian individuals. Methods. The investigation was done retrospectively on patients who were referred to the Department of Oral Radiology, Shiraz University of Medical Science, Shiraz, Iran. The patients were classified according to their blood groups, and 40 patients were randomly selected for each blood type. Therefore, the impaction of their third molars was evaluated, and statistical analyses were done in order to find any association. Results. A total of 320 participants contributed to the study; 136 (42%) were males and 184 (57%) were females. The mean age was 29 ± 6 years. Among all participants, 205 (64%) had no impacted third molar, 26 (8%) had one impacted third molar, 43 (13%) had 2 impacted third molars, 5 (1%) had 3 impacted third molars, and 41 (12%) had 4 impacted molars. Conclusion. According to the results of the present study, nearly one out of three individuals has at least an impacted third molar in the Iranian population, being more prevalent in individuals between 20 and 30 years old. The evaluation of the relationship between the blood group and impacted third molar revealed that blood groups have no association with the impacted third molars. However, more studies with higher and diversified participants should be done to find comprehensive results.

4 August 2020 in Hepatitis Monthly
Verified
Journal Article
Open access
PDF file
SHSahar Hosseini
Sahar Hosseini
AEAlireza Ebrahimi
Alireza Ebrahimi
FBFereshteh Bagheri
Fereshteh Bagheri
YEYasaman Emami
Yasaman Emami
EEElmira Esmaeilzadeh
Elmira Esmaeilzadeh
SESoheil Ashkani Esfahani
Soheil Ashkani Esfahani
Background: The current treatments of liver diseases are not sufficiently effective, and there has been no therapy that can successfully prevent liver failure and its complications. Previous studies have suggested that resveratrol could inhibit the progression of hepatic diseases based on its antioxidative and anti-inflammatory potentials. Objectives: The present study evaluated the hepato-protective effects of resveratrol in thioacetamide (TAA)-induced acute liver damage in rats using neurobehavioral and biochemical parameters. Methods: Forty-eight healthy adult Wistar rats were divided into four groups: C1: healthy control group, C2: non-treated liver failure, E1: liver failure treated with resveratrol 5 mg/kg/day, and E2: liver failure treated with resveratrol 10 mg/kg/day. Aspartate aminotransferase/alanine aminotransferase (AST/ALT), alkaline phosphatase (Alk), total bilirubin (TB), and plasma-ammonia (NH4) were analyzed, and histopathological evaluations of the specimens were carried out after sacrificing the models. Hepatic encephalopathy (HE) grading, open-field, elevated plus arms, and forced-swimming tests were performed in the study. Results: The resveratrol-treated groups had lower serum concentrations of NH4, ALT, and AST than the C2 group (P < 0.05). The pathological evaluations demonstrated that resveratrol-treated groups had better outcomes in inflammatory cell infiltration, apoptosis, vacuolization, liver tissue necrosis, and liver damage stage than the C2 group (P < 0.05). They also showed lower grades of HE, higher locomotor activity (open-field test), and diminished levels of depression (forced-swimming) when compared to the C2 group (P < 0.05). Conclusions: Resveratrol supplementation can improve liver damage as AST, ALT, NH4, and tissue damages were decreased after administering the agent in TAA-induced liver damage. Resveratrol can also improve the neurobehavioral manifestations in animal models of liver failure.

1 January 2023 in Journal of Orthopaedic Case Reports
Verified
Journal Article
Open access
AEAlireza Ebrahimi
Alireza Ebrahimi
SSSora Sohn
Sora Sohn
ALAndreea Lucaciu
Andreea Lucaciu
SASoheil Ashkani-Esfahani
Soheil Ashkani-Esfahani
GWGregory Waryasz
Gregory Waryasz
Introduction: Various methods are used for open reduction and internal fixation of Lisfranc injuries, and each shows different post-treatment outcomes. Other than the common post-surgery problems in these patients, including possible non-anatomical reduction, implant loosening, breakage, and arthritis, most of these patients will undergo a second surgery for implant removal which itself might cause further complications. To reduce the need for re-operation, bio-degradable or bio-integrative implants can be promising; however, the short- and long-term outcomes have been scarcely investigated to date. Case Report: We followed up 10 adult patients who received bio-integrative screws for Lisfranc injuries. The patients were asked to fill out the patient-reported outcome measures (PROMs) surveys during one of the follow-up visits. We gathered variables including the type of injury, pain score, and PROMs including physical function (PF), pain interference, pain intensity, and depression. We evaluated the patients for wound dehiscence, non-union, and hardware failure. The median (interquartile range [IQR]) follow-up time of the patients in this study was 9 (4–11.5) months. Nine out of 10 patients with Lisfranc injuries who received bio-integrative screws showed improvements in their pain scores and started progressive weight-bearing. Among 3 patients who had sport-related Lisfranc injuries, 2 returned to play in <6 months, and one started side-to-side agility work in <3 months. The median (IQR) scores of PROMs representing PF, depression, physical health, mental health, pain interference, and pain intensity were 49.5 (30.1–61.9), 41 (41–49), 50.8 (39.2–57.7), 59 (48.9–63.7), 51.7 (41.6–72.6), and 43.5 (37.8–55.2), respectively. Conclusion: Our results demonstrated promising short-term outcomes of using bio-integrative screws in patients with Lisfranc injuries based on PROMs and the rate of complications. Future studies on larger populations and more comprehensive variables with longer follow-up duration should be the next step in evaluating the pros and cons of these new implants. Keywords: Bio-integrative implant, revision surgery, implant removal, Lisfranc complications.